+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hypolipidemics Global Market Report 2021: COVID-19 Impact and Recovery to 2030

  • ID: 5351792
  • Report
  • June 2021
  • Region: Global
  • The Business Research Company

FEATURED COMPANIES

  • Amgen
  • Biocon Limited
  • Croda Europe Limited Leek
  • Hikal
  • Lek Pharmaceuticals d.d.
  • Moehs Iberica S.L. ES
Hypolipidemics Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global hypolipidemics market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the hypolipidemics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Hypolipidemics Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:

1) By Product Type: Cholic Acid Regulator; HMG-CoA Reductase Inhibitors; Adenylate Cyclase Inhibitors; Nicotinic Acid Drugs; Others
2) By Application: Hospital; Clinics; Pharmacy; Cardiovasology

Companies Mentioned: ABBOTT LABORATORIES LIMITED; Apotex Fermentation Inc.; BIOCON LIMITED; Cadila Healthcare Limited; Chunghwa Chem Syn& Biotech

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Biocon Limited
  • Croda Europe Limited Leek
  • Hikal
  • Lek Pharmaceuticals d.d.
  • Moehs Iberica S.L. ES
1. Executive Summary

2. Hypolipidemic Drugs Market Characteristics

3. Hypolipidemic Drugs Market Trends And Strategies

4. Impact Of COVID-19 On Hypolipidemic Drugs

5. Hypolipidemic Drugs Market Size And Growth
5.1. Global Hypolipidemic Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Hypolipidemic Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Hypolipidemic Drugs Market Segmentation
6.1. Global Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Cholic Acid Regulator
  • HMG-CoA Reductase Inhibitors
  • Adenylate Cyclase Inhibitors
  • Nicotinic Acid Drugs
  • Others
6.2. Global Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital
  • Clinics
  • Pharmacy
  • Cardiovasology
7. Hypolipidemic Drugs Market Regional And Country Analysis
7.1. Global Hypolipidemic Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Hypolipidemic Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Hypolipidemic Drugs Market
8.1. Asia-Pacific Hypolipidemic Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Hypolipidemic Drugs Market
9.1. China Hypolipidemic Drugs Market Overview
9.2. China Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Hypolipidemic Drugs Market
10.1. India Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Hypolipidemic Drugs Market
11.1. Japan Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Hypolipidemic Drugs Market
12.1. Australia Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Hypolipidemic Drugs Market
13.1. Indonesia Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Hypolipidemic Drugs Market
14.1. South Korea Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Hypolipidemic Drugs Market
15.1. Western Europe Hypolipidemic Drugs Market Overview
15.2. Western Europe Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Hypolipidemic Drugs Market
16.1. UK Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Hypolipidemic Drugs Market
17.1. Germany Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Hypolipidemic Drugs Market
18.1. France Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.2. France Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Hypolipidemic Drugs Market
19.1. Eastern Europe Hypolipidemic Drugs Market Overview
19.2. Eastern Europe Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Hypolipidemic Drugs Market
20.1. Russia Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Hypolipidemic Drugs Market
21.1. North America Hypolipidemic Drugs Market Overview
21.2. North America Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Hypolipidemic Drugs Market
22.1. USA Hypolipidemic Drugs Market Overview
22.2. USA Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Hypolipidemic Drugs Market
23.1. South America Hypolipidemic Drugs Market Overview
23.2. South America Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Hypolipidemic Drugs Market
24.1. Brazil Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Hypolipidemic Drugs Market
25.1. Middle East Hypolipidemic Drugs Market Overview
25.2. Middle East Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Hypolipidemic Drugs Market
26.1. Africa Hypolipidemic Drugs Market Overview
26.2. Africa Hypolipidemic Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Hypolipidemic Drugs Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Hypolipidemic Drugs Market Competitive Landscape And Company Profiles
27.1. Hypolipidemic Drugs Market Competitive Landscape
27.2. Hypolipidemic Drugs Market Company Profiles
27.2.1. ABBOTT LABORATORIES LIMITED
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Apotex Fermentation Inc.
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. BIOCON LIMITED IN Bangalore
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Cadila Healthcare Limited
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Chunghwa Chem Syn& Biotech Co., Ltd
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. Hypolipidemic Drugs Pipeline Analysis

29. Key Mergers And Acquisitions In The Hypolipidemic Drugs Market

30. Hypolipidemic Drugs Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Biocon Limited
  • Croda Europe Limited Leek
  • Hikal
  • Lek Pharmaceuticals d.d.
  • Moehs Iberica S.L. ES
Major players in the hypolipidemic drugs market are ABBOTT LABORATORIES LIMITED, Apotex Fermentation Inc., Biocon Limited, Cadila Healthcare Limited and Chunghwa Chem Syn& Biotech Co., Ltd.

The global hypolipidemics market is expected to decline from $16.23 billion in 2020 to $15.94 billion in 2021 at a compound annual growth rate (CAGR) of -1.8%. The decline is mainly due to the companies' production being impacted negatively by COVID-19, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $18.41 billion in 2025 at a CAGR of 3.7%.

The hypolipidemic drugs market consists of sales of hypolipidemic drugs and related services. This industry includes establishments that produce hypolipidemic drugs or agents that lower lipid and lipoproteins levels in the blood. These drugs can be used to prevent cardiovascular diseases and atherosclerosis in Hyperlipidemia patients. Some of the major hypolipidemic drugs include fibric acid derivatives, bile acid binding resins, nicotinamides, and cholesterol absorption inhibitors.

The market covered in this report is segmented by product type into cholic acid regulator, HMG-CoA reductase inhibitors, adenylate cyclase inhibitors, nicotinic acid drugs, others; by application into hospital, clinics, pharmacy, cardiovasology.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Shifts in diet and change in lifestyles of people is driving the growth of hypolipidemic drugs market. Increase in the consumption of unhealthy food, rising prevalence of smoking and drinking have led to an increase in the level of cholesterol intake by the people. According to a study by Global Burden of Disease (GBD) in 2019, high blood pressure contributed to almost 1.47 million deaths in India. The rising levels of cholesterol due to change in lifestyles of the people is rising demand for hypolipidemic drugs as they aid in lowering the cholesterol levels.

Companies in this market are increasingly investing in using data generated from wearables in clinical trials to improve the speed, and efficiency of trials, and therefore reduce overall costs. By continuously capturing data from patients via wearable technologies, clinical trial sponsors may be able to reduce the burden of frequent site visits, which could improve patient dropout rates and overall clinical trial efficiencies. The use of wearables helps to tackle the challenge of patient recruitment, helps in monitoring patients, gives accurate and real time data and gives earlier decision-making opportunities, while the patient is undergoing a clinical trial. Pharmaceutical companies such as Sanofi and Pfizer have already invested in wearable technology to treat hypolipidemia.

The growth in the usage of biologics acts as a prime restraint that hinders the hypolipidemic drug market growth. Biologics are derived from living organisms like human beings, animals and microorganisms, different from chemical drugs or chemically synthesized drugs. The increasing preference towards hypolipidemic biologic medicines due to side effects concerns of using chemical synthesized drugs leads to decrease in the sales of traditional hypolipidemic chemical drugs and hence, hindering the hypolipidemic drug (chemical) market growth. According to Harvard Medical School, 10%-29% people who consume hypolipidemic drugs such as cholesterol-lowering statin drugs are suffering from muscle pains and aches. For instance, PCSK9 Inhibitors have been in use since 2015, to reduce LDL cholesterol. Amgens’ Repatha, a hypolipidemic biologic medicine, got the FDA approval for the treatment of hypolipidemia.

The EU agencies take 6 to 12 months to approve the hypolipidemic drugs. Moreover it requires all parts of the registration dossier to be submitted together unlike the US-FDA which accepts phased submissions. The US-FDA assess each technical section in 6 months which may increase to another 6 months if questions/concerns are raised. However, the technical sections’ assessment is done simultaneously and therefore the manufacturers should identify the time taking steps and plan the work accordingly and chalk out an estimated date of approval. Also, the license validity and renewal of the application in EU region takes a toll on the manufacturer and adds to the existing regulatory burden. Therefore, the manufacturers hypolipedimic drugs should plan well, communicate effectively in order to minimize the costs and reduce timelines.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown
  • Abbott Laboratories Limited
  • Apotex Fermentation Inc.
  • Biocon Limited
  • Cadila Healthcare Limited
  • Chunghwa Chem Syn& Biotech Co. Ltd
  • Concord Biotech Limited
  • Croda Europe Limited Leek
  • Daiichi Sankyo Company Limited
  • Dr. Reddy’s Laboratories Ltd
  • DSM Sinochem Pharma India
  • Hikal
  • Ipca Laboratories
  • Lek Pharmaceuticals d.d.
  • Lupin Limited
  • Merck Sharp & Dohme B.V.
  • Mylan N.V.
  • Nexchem Pharmaceutical Co. Ltd. CN
  • Olon S.p.A.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zhejiang Jiangbei Pharma Co. Ltd CN.
  • Moehs Iberica S.L. ES
  • Pfizer Inc
  • Recordati S.p.A. IT Milano
  • AstraZeneca
  • Amgen
  • Daiichi Sankyo
  • Kowa Company Ltd.
  • Sanofi
  • Novartis
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll